Literature DB >> 8281088

Guillain-Barré syndrome after exogenous gangliosides in Italy.

G Landi1, R D'Alessandro, B C Dossi, S Ricci, I L Simone, A Ciccone.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8281088      PMCID： PMC1679501          DOI： 10.1136/bmj.307.6917.1463

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  3 in total

1.  Guillain-Barré syndrome and ganglioside therapy in Italy.

Authors:  R Raschetti; M Maggini; P Popoli
Journal:  Lancet       Date:  1992-07-04       Impact factor: 79.321

2.  Bovine gangliosides and acute motor polyneuropathy.

Authors:  A Figueras; F J Morales-Olivas; D Capellà; V Palop; J R Laporte
Journal:  BMJ       Date:  1992-11-28

3.  Ganglioside therapy and Guillain-Barré syndrome. A historical cohort study in Ferrara, Italy, fails to demonstrate an association.

Authors:  E Granieri; I Casetta; V Govoni; M R Tola; E Paolino; W A Rocca
Journal:  Neuroepidemiology       Date:  1991       Impact factor: 3.282
  3 in total
  11 in total

1.  Epidemiology of peripheral neuropathy.

Authors:  C N Martyn; R A Hughes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-04       Impact factor: 10.154

2.  Gangliosides and Guillain-Barré syndrome. Apparent association is a coincidence.

Authors:  F Grigoletto
Journal:  BMJ       Date:  1994-03-05

3.  Gangliosides and Guillain-Barré syndrome. No causal link.

Authors:  J C Samson; M G Fiori
Journal:  BMJ       Date:  1994-03-05

4.  Gangliosides and the Guillain-Barré syndrome.

Authors:  G Landi; A Ciccone; R D'Alessandro; B C Dossi; S Ricci; I L Simone
Journal:  BMJ       Date:  1994-06-18

Review 5.  FK506 and the role of immunophilins in nerve regeneration.

Authors:  B G Gold
Journal:  Mol Neurobiol       Date:  1997-12       Impact factor: 5.590

Review 6.  Limiting neurological damage after stroke: a review of pharmacological treatment options.

Authors:  S J Read; T Hirano; S M Davis; G A Donnan
Journal:  Drugs Aging       Date:  1999-01       Impact factor: 3.923

Review 7.  Gangliosides. Their role in clinical neurology.

Authors:  E Nobile-Orazio; M Carpo; G Scarlato
Journal:  Drugs       Date:  1994-04       Impact factor: 9.546

8.  Gangliosides and Guillain-Barré syndrome. Science supports the use of gangliosides.

Authors:  M Massarotti; R Matano
Journal:  BMJ       Date:  1994-03-05

9.  A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients.

Authors:  Jay S Schneider; Stephen M Gollomp; Stephanie Sendek; Amy Colcher; Franca Cambi; Wei Du
Journal:  J Neurol Sci       Date:  2012-11-28       Impact factor: 3.181

Review 10.  Guillain-Barré syndrome and anti-ganglioside antibodies: a clinician-scientist's journey.

Authors:  Nobuhiro Yuki
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2012       Impact factor: 3.493
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.